LAB3726
This test is only for use by the Pain Managment clinics.
Effective 3/2/15: This testing will be done by PCL Clinical Laboratory.
Collect
Random urine.
Specimen Preparation
Transfer 4 mL each into two (2) ARUP Standard Transport Tubes urine with no additives or preservatives. (Min: 2 mL each)
Unacceptable Conditions
Specimens exposed to repeated freeze/thaw cycles.
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years
Performed by
PCL Clinical Laboratory in Salt Lake City,UT.
Notes
Creatinine concentration is also provided. The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.
Performed
Sun-Sat
Methodology
Qualitative Liquid Chromatography/Time of Flight Mass Spectrometry/Enzyme Immunoassay/Quantitative Spectrophotometry
Reported
1-3 days
Synonyms
- LAB3726
- PAIN HYB U
- URPAINTOX
Reference Interval
Effective November 17, 2014
Drugs covered and range of cutoff concentrations. Note that some drugs are identified based on the presence of unique drug metabolites not listed below. | |
Drugs/Drug Classes | Range of Cutoff Concentrations |
Barbiturates | 200 ng/mL |
Benzodiazepine-like: alprazolam, clonazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam, zolpidem | 20 - 60 ng/mL |
Cannabinoids (11-nor-9-carboxy-THC) | 20 ng/mL |
Ethyl Glucuronide | 500 ng/mL |
Muscle Relaxant(s): carisoprodol, meprobamate | 100 ng/mL |
Opiates/Opioids: buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone, propoxyphene, tapentadol, tramadol | 2-300 ng/mL |
Phencyclidine (PCP) | 25 ng/mL |
Stimulants: amphetamine, cocaine, methamphetamine, methylphenidate, MDMA (Ecstasy), MDEA (Eve), MDA, phentermine | 100-400 ng/mL |
Interpretive Data
Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Time-of-Flight-Mass Spectrometry, Quantitative Spectrophotometry
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.
Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.
For medical purposes only; not valid for forensic use.
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.
Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.
For medical purposes only; not valid for forensic use.
Performed by
PCL Clinical Laboratory in Salt Lake City,UT.
CPT Codes
80304; 80301; 80302 x3; (Alt code: G0431)
Collection |
LAB3726
This test is only for use by the Pain Managment clinics.
Effective 3/2/15: This testing will be done by PCL Clinical Laboratory.
Collect
Random urine.
Specimen Preparation
Transfer 4 mL each into two (2) ARUP Standard Transport Tubes urine with no additives or preservatives. (Min: 2 mL each)
Unacceptable Conditions
Specimens exposed to repeated freeze/thaw cycles.
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years
Performed by
PCL Clinical Laboratory in Salt Lake City,UT.
Notes
Creatinine concentration is also provided. The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.
Ordering |
Performed
Sun-Sat
Methodology
Qualitative Liquid Chromatography/Time of Flight Mass Spectrometry/Enzyme Immunoassay/Quantitative Spectrophotometry
Reported
1-3 days
Synonyms
- LAB3726
- PAIN HYB U
- URPAINTOX
Result Interpretation |
Reference Interval
Effective November 17, 2014
Drugs covered and range of cutoff concentrations. Note that some drugs are identified based on the presence of unique drug metabolites not listed below. | |
Drugs/Drug Classes | Range of Cutoff Concentrations |
Barbiturates | 200 ng/mL |
Benzodiazepine-like: alprazolam, clonazepam, diazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam, zolpidem | 20 - 60 ng/mL |
Cannabinoids (11-nor-9-carboxy-THC) | 20 ng/mL |
Ethyl Glucuronide | 500 ng/mL |
Muscle Relaxant(s): carisoprodol, meprobamate | 100 ng/mL |
Opiates/Opioids: buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone, propoxyphene, tapentadol, tramadol | 2-300 ng/mL |
Phencyclidine (PCP) | 25 ng/mL |
Stimulants: amphetamine, cocaine, methamphetamine, methylphenidate, MDMA (Ecstasy), MDEA (Eve), MDA, phentermine | 100-400 ng/mL |
Interpretive Data
Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Time-of-Flight-Mass Spectrometry, Quantitative Spectrophotometry
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.
Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.
For medical purposes only; not valid for forensic use.
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.
Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.
For medical purposes only; not valid for forensic use.
Performed by
PCL Clinical Laboratory in Salt Lake City,UT.
Administrative |
CPT Codes
80304; 80301; 80302 x3; (Alt code: G0431)